Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.

about

Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q55007608

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@en

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@nl

type

Item

label

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@en

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@nl

prefLabel

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@en

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@nl

P1476

Risk of hepatitis B reactivati ...... for chronic myeloid leukemia.

@en

P2093

Chiara Elena

http://www.w3.org/2001/XMLSchema#string

Elisa Bono

http://www.w3.org/2001/XMLSchema#string

Ester Maria Orlandi

http://www.w3.org/2001/XMLSchema#string

P2860

Management of patients with hepatitis B who require immunosuppressive therapy

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy.

Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.

Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy

P304

1764-1766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2016.1260127

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27892750

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia